WHAT IS CLAIMED IS:

1. Use of an antibody or antigen-binding fragment thereof that specifically binds to a *Staphylococcus aureus* (*S. aureus*) alpha toxin antigen in the manufacture of a medicament for treating or preventing a polybacterial infection in a patient, wherein the antibody or antigen-binding fragment thereof is to be administered to the patient, wherein the polybacterial infection comprises *S. aureus* and at least one gram-negative bacterium, wherein the *S. aureus* alpha toxin potentiates the growth of the at least one gram-negative bacterium; and wherein the antibody or antigen-binding fragment thereof that binds to *S. aureus* alpha toxin binds to the same alpha toxin epitope as an antibody comprising the VH and VL sequences of SEQ ID NOs: 45 and 46.

2. The use of claim 1, wherein the at least one gram-negative bacterium is *Pseudomonas, Klebsiella* or *Acinetobacter*.

3. The use of claim 2, wherein the *Pseudomonas* is *Pseudomonas aeruginosa* (*P. aeruginosa*), the *Klebsiella* is *Klebsiella pneumonia*e (*K. pneumoniae*) or the *Acinetobacter* is *Acinetobacter baumannii* (*A. baumannii*).

4. Use of an antibody or antigen-binding fragment thereof that specifically binds to *S. aureus* alpha toxin in the manufacture of a medicament for inhibiting the growth of *P. aeruginosa* in a patient, wherein the antibody or antigen-binding fragment thereof that specifically binds to a *S. aureus* antigen is to be administered to the patient; and wherein the antibody or antigen-binding fragment thereof that binds to *S. aureus* alpha toxin binds to the same alpha toxin epitope as an antibody comprising the VH and VL sequences of SEQ ID NOs: 45 and 46.

5. The use of any one of claims 1-4, wherein the antibody or antigen-binding fragment thereof comprises the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of SEQ ID NOs:57, 58, 59, 1, 2 and 56.

6. The use of claim 5, wherein antibody or antigen-binding fragment thereof comprises the VH and VL sequences of SEQ ID NOs:45 and 46.

7. The use of claim 5, wherein the antibody or antigen-binding fragment thereof that specifically binds to *S. aureus* alpha toxin comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 68 and a light chain comprising the amino acid sequence of SEQ ID NO:69.

8. The use of any one of claims 1-5, wherein the antibody of antigen-binding fragment thereof is an IgG antibody of antigen-binding fragment thereof.

9. The use of claim 8, wherein the IgG antibody comprises the YTE substitutions of M252Y, S254T, and T256E, wherein the numbering is according to the EU index.

10. The use of any one of claims 1-9, wherein the polybacterial infection is an ocular infection, a lung infection, a burn infection, a wound infection, a surgical wound infection, a skin infection, a soft tissue infection, a blood infection, a bone infection, or a combination of two or more of said infections.

11. The use of any one of claims 1-10, wherein the patient has acute pneumonia, burn injury, corneal infection, cystic fibrosis, ventilator-associated pneumonia, a skin infection, a wound infection, or a combination thereof.

12. The use of any one of claims 1-11, wherein the polybacterial infection is a nosocomial infection.